Hyperovulation Induction for Assisted Reproduction Treatment
Conditions
Brief summary
The purpose of this study is to compare the efficacy and safety of DA-3803(r-hCG) and Ovidrel for inducting final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment
Detailed description
This is an single-blind, randomized, comparative multicentric, phase III study to evaluate the safety and efficacy of DA-3803(r-hCG) in comparison with Ovidrel in the induction of final follicle maturation and early luteinization in 180 Korean female subjects undergoing superovulation. The study is organized on an outpatient basis in subjects undergoing assisted reproductive technologies (ART). The subjects are randomized into 2 groups. One group receive DA-3803(r-hCG) 250mcg and the other group receive Ovidrel®(r-hCG)250mcg. Each subject in both groups receives a single injection of hCG when the follicular development was judged to be adequate. Oocytes are retrieved 34-38 hours after r-hCG injection and fertilized in vitro. Not more than 4 embryos are to be replaced. Progesterone is administered daily according to center's normal practice, starting after the oocyte pick up and continuing until appropriate time. The subject is followed up and the treatment outcome (negative pregnancy test or pregnancy) is recorded.
Interventions
DRUGr-hCG
r-hCG(250mcg) injection subcutaneously
Sponsors
Dong-A Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No
Inclusion criteria
* Infertility regular ovulatory menstrual cycles : 25\ 35days * BMI\<=30kg/m2 * Early follicular phase serum levels are normal : FSH, LH, prolactin, testosterone * Both ovaries present and clinically normal uterine cavity * \< 3 previous ART cycles, no ART cycles for 2 menstrual cycles * semen analysis and ART are possible * informed couple consent
Exclusion criteria
* With a poor response to gonadotrophin stimulation, such as ≤3 oocytes collected in any previous ART cycle * Had previous severe ovarian hyperstimulation syndrome(OHSS) * Polycystic ovarian syndrome(PCOS) * Extra-uterine pregnancy within the last 3 months * A clinically significant uncontrolled endocrine diseases, chronic cardiovascular disorders, hepatic, pulmonary and renal diseases * Known allergy,hypersensitivity or contraindication to FSH, hCG, progesterone and GnRH antagonists * medication with human gonadotrophin preparations(FSH, LH, hCG) within 2 months * participation in another clinical trial within 1 month
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the efficacy and safety of DA-3803(r-hCG) | about 1 month after ART | the number of oocytes retrieved per patient following r-hCG administration, physical examination, clinical laboratory measurements, adverse events, injection-sited reactions, OHSS, number of multiple pregnancies |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the efficacy of DA-3803(r-hCG) | about 1 month after ART | number of patients who received r-hCG with at least one oocyte retrieved, number of oocyte retrieved per number of follicles \>10mm diameter on the day of r-hCG, number of mature oocytes, number of 2PN fertilized oocytes, number of 2PN cleaved embryos, implantation rate per embryo transferred, number of biochemical and clinical pregnancies |
Countries
South Korea
Outcome results
None listed